Andere talen 3D Medicines Inc.

Aandelen

1244

KYG8872R1011

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:10 26-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,64 ^HKD	-2,42%		-3,92%	-26,18%

05/06	3D Medicines benoemt nieuwe accountants	MT
29/03	3D Medicines' verlies in 2023 bijna gehalveerd terwijl de omzet met 12% is gestegen	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

3D Medicines to Appoint New Auditors	05/06
3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12%	29/03
3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	19/02
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	19/02
3D Medicines Inc. commences an Equity Buyback Plan for 25,605,700 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2023.	31/01
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 for Multiple Geographies around the World	26/01
Alphamab Oncology and 3Dmedicines Enters into A Licensing Agreement with Glenmark for KN035	25/01
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable	25/01
3D Medicines Unit Receives Repayment for 60 Million Yuan Loan	22/01
3D Medicines Subsidiary Extends 60 Million Yuan Loan; Shares Fall 3%	04/01
SELLAS Life Sciences Seeks Arbitration in Dispute with 3D Medicines	27/12
3D Medicines Inc. Announces Change of Principal Place of Business in Hong Kong	27/12
35,992,364 Ordinary Shares of 3D Medicines Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2023.	14/12
3D Medicines Gets US FDA's Nod to Trial Envafolimab; Shares Soar 24%	30-10-23
3D Medicines Inc. Receives Approval from Fda to Proceed with Aglobal Phase Iii Trial for Treatment of the First Line Mismatch Repair ProficientAdvanced or Recurrent Endometrial Cancer	30-10-23
Sellas Life Sciences Expects to Complete Patient Enrollment for Phase 3 REGAL Trial in November	12-10-23
128,967,484 Ordinary Shares of 3D Medicines Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.	30-09-23
3D Medicines Invests Over $21 Million of Surplus Cash	26-09-23
3D Medicines Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	25-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen 3D Medicines Inc.

Aandelen

1244

KYG8872R1011

Andere talen

Filters